NCT03513588View on ClinicalTrials.gov

2-Week Study In People With Nonalcoholic Fatty Liver Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 21, 2018

Primary Completion Date

March 8, 2019

Study Completion Date

April 4, 2019

Conditions
Non-alcoholic SteatohepatitisNon-alcoholic Fatty Liver Disease
Interventions
DRUG

Placebo

tablet, 0 mg, 14 days, every 12 hours

DRUG

PF-06865571

tablet, 50 mg, 14 days, every 12 hours

DRUG

PF-06865571

tablet, 300 mg, 14 days, every 12 hours

Trial Locations (6)

27265

High Point Clinical Trials Center, High Point

33143

Qps-Mra, Llc, South Miami

78229

Clinical Trials of Texas, Inc., San Antonio

89113

PPD Development, LP, Las Vegas

92801

Anaheim Clinical Trials, LLC, Anaheim

06511

New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03513588 - 2-Week Study In People With Nonalcoholic Fatty Liver Disease | Biotech Hunter | Biotech Hunter